Item 199 (Not set out) | First Year - FY2009 | Second Year - FY2010 |
---|
|
|
Financial Assistance for Educational and General Services (11000) | $281,757,011 | $294,857,011 |
Eminent Scholars (11001) | FY2009 $4,136,084 | FY2010 $4,136,084 |
Sponsored Programs (11004) | FY2009 $277,620,927 | FY2010 $290,720,927 |
Fund Sources: | | |
General | FY2009 $3,146,875 | FY2010 $3,146,875 |
Higher Education Operating | FY2009 $267,070,136 | FY2010 $280,170,136 |
Debt Service | FY2009 $11,540,000 | FY2010 $11,540,000 |
Authority: Title 23, Chapter 9, Code of Virginia.
A. Out of this appropriation, $2,146,875 each year from the general fund and $14,350,000 each year from nongeneral funds is designated to build research capacity in the areas of bioengineering and regenerative medicine.
B. The University of Virginia shall report on the use of these funds and the progress made under this initiative to the Chairmen of the House Appropriations and Senate Finance Committees by October 1, 2008. The report shall include, but not be limited to: 1) how the funds were used, 2) the amount of federal and private funds that were leveraged, 3) collaborative efforts in support of private industry, 4) the number of junior and senior faculty recruited in each field, 5) the amount of federal or other grant funds received as the result of those recruitments, 6) additional grants or contracts being pursued, 7) the level of instructional activity conducted by these faculty, 8) the impact of research activities on undergraduate instruction, 9) the use of graduate student aid funds, and 10) recommendations for future investment.
C. Out of this appropriation, $1,000,000 each year from the general fund is designated for the support of cancer research.
D. The Higher Education Operating fund source listed in this Item is considered to be a sum sufficient appropriation, which is an estimate of funding required by the university to cover sponsored program operations.